vs

Side-by-side financial comparison of Cellectis S.A. (CLLS) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.

Idaho Strategic Resources, Inc. is the larger business by last-quarter revenue ($14.6M vs $9.5M, roughly 1.5× Cellectis S.A.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -265.9%, a 330.2% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 92.0%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $8.2M).

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.

CLLS vs IDR — Head-to-Head

Bigger by revenue
IDR
IDR
1.5× larger
IDR
$14.6M
$9.5M
CLLS
Growing faster (revenue YoY)
CLLS
CLLS
+282.9% gap
CLLS
375.0%
92.0%
IDR
Higher net margin
IDR
IDR
330.2% more per $
IDR
64.3%
-265.9%
CLLS
More free cash flow
CLLS
CLLS
$19.4M more FCF
CLLS
$27.6M
$8.2M
IDR

Income Statement — Q2 FY2024 vs Q4 FY2025

Metric
CLLS
CLLS
IDR
IDR
Revenue
$9.5M
$14.6M
Net Profit
$-25.3M
$9.4M
Gross Margin
68.5%
Operating Margin
-181.1%
62.4%
Net Margin
-265.9%
64.3%
Revenue YoY
375.0%
92.0%
Net Profit YoY
-51.9%
220.6%
EPS (diluted)
$-0.28
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLLS
CLLS
IDR
IDR
Q4 25
$14.6M
Q3 25
$11.1M
Q2 25
$9.5M
Q1 25
$7.3M
Q4 24
$7.6M
Q3 24
$6.2M
Q2 24
$9.5M
$6.1M
Q1 24
$5.9M
Net Profit
CLLS
CLLS
IDR
IDR
Q4 25
$9.4M
Q3 25
$3.0M
Q2 25
$2.8M
Q1 25
$1.6M
Q4 24
$2.9M
Q3 24
$1.6M
Q2 24
$-25.3M
$2.2M
Q1 24
$2.2M
Gross Margin
CLLS
CLLS
IDR
IDR
Q4 25
68.5%
Q3 25
63.6%
Q2 25
57.8%
Q1 25
50.8%
Q4 24
53.3%
Q3 24
48.7%
Q2 24
50.2%
Q1 24
48.1%
Operating Margin
CLLS
CLLS
IDR
IDR
Q4 25
62.4%
Q3 25
23.4%
Q2 25
26.6%
Q1 25
19.3%
Q4 24
36.2%
Q3 24
23.4%
Q2 24
-181.1%
34.2%
Q1 24
36.3%
Net Margin
CLLS
CLLS
IDR
IDR
Q4 25
64.3%
Q3 25
26.8%
Q2 25
29.2%
Q1 25
22.1%
Q4 24
38.5%
Q3 24
25.8%
Q2 24
-265.9%
35.2%
Q1 24
36.8%
EPS (diluted)
CLLS
CLLS
IDR
IDR
Q4 25
$0.62
Q3 25
$0.20
Q2 25
$0.20
Q1 25
$0.12
Q4 24
$0.21
Q3 24
$0.12
Q2 24
$-0.28
$0.17
Q1 24
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLLS
CLLS
IDR
IDR
Cash + ST InvestmentsLiquidity on hand
$149.0M
Total DebtLower is stronger
$2.3M
Stockholders' EquityBook value
$148.6M
$108.2M
Total Assets
$407.1M
$116.2M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLLS
CLLS
IDR
IDR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$149.0M
$6.3M
Q1 24
$5.3M
Total Debt
CLLS
CLLS
IDR
IDR
Q4 25
$2.3M
Q3 25
$3.0M
Q2 25
$3.3M
Q1 25
$3.7M
Q4 24
$1.7M
Q3 24
$2.9M
Q2 24
$2.7M
Q1 24
$3.3M
Stockholders' Equity
CLLS
CLLS
IDR
IDR
Q4 25
$108.2M
Q3 25
$74.3M
Q2 25
$49.3M
Q1 25
$39.8M
Q4 24
$37.7M
Q3 24
$33.1M
Q2 24
$148.6M
$25.4M
Q1 24
$21.6M
Total Assets
CLLS
CLLS
IDR
IDR
Q4 25
$116.2M
Q3 25
$83.1M
Q2 25
$57.7M
Q1 25
$48.1M
Q4 24
$44.0M
Q3 24
$40.8M
Q2 24
$407.1M
$32.2M
Q1 24
$28.7M
Debt / Equity
CLLS
CLLS
IDR
IDR
Q4 25
0.02×
Q3 25
0.04×
Q2 25
0.07×
Q1 25
0.09×
Q4 24
0.05×
Q3 24
0.09×
Q2 24
0.11×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLLS
CLLS
IDR
IDR
Operating Cash FlowLast quarter
$28.9M
$10.7M
Free Cash FlowOCF − Capex
$27.6M
$8.2M
FCF MarginFCF / Revenue
290.5%
56.0%
Capex IntensityCapex / Revenue
13.2%
17.7%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$12.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLLS
CLLS
IDR
IDR
Q4 25
$10.7M
Q3 25
$2.4M
Q2 25
$3.5M
Q1 25
$2.4M
Q4 24
$3.2M
Q3 24
$2.5M
Q2 24
$28.9M
$2.6M
Q1 24
$2.6M
Free Cash Flow
CLLS
CLLS
IDR
IDR
Q4 25
$8.2M
Q3 25
$709.8K
Q2 25
$2.5M
Q1 25
$1.0M
Q4 24
$2.1M
Q3 24
$1.9M
Q2 24
$27.6M
$2.4M
Q1 24
$2.3M
FCF Margin
CLLS
CLLS
IDR
IDR
Q4 25
56.0%
Q3 25
6.4%
Q2 25
26.5%
Q1 25
13.8%
Q4 24
28.0%
Q3 24
30.4%
Q2 24
290.5%
38.7%
Q1 24
38.3%
Capex Intensity
CLLS
CLLS
IDR
IDR
Q4 25
17.7%
Q3 25
15.3%
Q2 25
10.8%
Q1 25
19.4%
Q4 24
13.6%
Q3 24
9.8%
Q2 24
13.2%
4.3%
Q1 24
5.5%
Cash Conversion
CLLS
CLLS
IDR
IDR
Q4 25
1.15×
Q3 25
0.81×
Q2 25
1.28×
Q1 25
1.50×
Q4 24
1.08×
Q3 24
1.56×
Q2 24
1.22×
Q1 24
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons